Novel emerging therapies in atherosclerosis targeting lipid metabolism.
Manasvi GuptaColin BlumenthalSubhankar ChatterjeeDhrubajyoti BandyopadhyayVardhmaan JainCarl J LavieSalim S ViraniKausik K RayWilbert S AronowRaktim K GhoshPublished in: Expert opinion on investigational drugs (2020)
New options now exist for the prevention of atherosclerosis in patients that are not optimized on statin therapy. Multiple guidelines endorse ezetimibe, PCSK9 inhibitors, bempedoic, and IPE as add-on therapy. Recently approved bempedoic acid/ezetimibe combination might gain popularity among clinicians. Inclisiran and pemafibrate show promise in the reduction of LDL-C and TG, respectively, and results are pending in cardiovascular outcome trials. Combination strategies could improve outcomes, but the challenge will be balancing cost and selecting the correct patient population for each treatment modality to maximize benefit with the fewest medications.
Keyphrases
- cardiovascular disease
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- low density lipoprotein
- prognostic factors
- coronary artery disease
- palliative care
- type diabetes
- metabolic syndrome
- cancer therapy
- machine learning
- mesenchymal stem cells
- fatty acid
- replacement therapy
- drug administration